TY  - BOOK
AU  - Schmidt,Stefan R.
TI  - Fusion protein technologies for biopharmaceuticals: applications and challenges 
SN  - 9781118354582
AV  - RM301.4 .F87 2013
U1  - 615.7 23
PY  - 2013///
CY  - Hoboken, New Jersey
PB  - John Wiley & Sons
KW  - Biopharmaceutics
KW  - Pharmaceutical biotechnology
KW  - Drug carriers
KW  - Immunotoxins
KW  - Therapeutic use
KW  - Protein engineering
KW  - Recombinant fusion proteins
KW  - MEDICAL
KW  - Pharmacology
KW  - bisacsh
KW  - fast
KW  - Recombinant Fusion Proteins
KW  - therapeutic use
KW  - Drug Carriers
KW  - pharmacokinetics
KW  - Protein Engineering
KW  - Electronic books
KW  - local
N1  - Includes bibliographical references and index; pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm; btbi
N2  - The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei
UR  - http://dx.doi.org/10.1002/9781118354599
ER  -